Kim S, Kim KH, Kim BK, Park JY, et al. Lenvatinib is independently associated with the reduced risk of progressive disease when compared to sorafenib in patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2020 Nov 20. doi: 10.1111/jgh.15355.
PMID: 33217054